Medtronic MDT Diabetes — Selling, general, and administrative expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Medtronic’s 10-Q, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's diabetes — selling, general, and administrative expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's diabetes — selling, general, and administrative expense?
- Medtronic (MDT) reported diabetes — selling, general, and administrative expense of $300M in Q4 2025.
- How has Medtronic's diabetes — selling, general, and administrative expense changed year-over-year?
- Medtronic's diabetes — selling, general, and administrative expense increased by 12.8% year-over-year, from $266M to $300M.
- What is the long-term trend for Medtronic's diabetes — selling, general, and administrative expense?
- Over 2 years (2023 to 2025), Medtronic's diabetes — selling, general, and administrative expense has grown at a 6.0% compound annual growth rate (CAGR), from $705M to $792M.
- What does diabetes — selling, general, and administrative expense mean?
- The costs of selling, marketing, and managing the administrative side of the diabetes business.
- How do you interpret diabetes — selling, general, and administrative expense?
- A decrease relative to sales suggests improved operating leverage, while an increase may indicate higher investment in sales force expansion.
- How does diabetes — selling, general, and administrative expense compare across companies?
- Standard SG&A expense metric used across all industries for business segments.